Philippine Food and Drug Administration Recalls Cholesterol Drug and Tuberculosis Medication

Philippine FDA Recalls Cholesterol Drug
Philippine FDA Recalls Cholesterol Drug

Philippine FDA Recalls Cholesterol Drug
Philippine FDA Recalls Cholesterol Drug

The Food and Drug Administration (FDA) of the Philippines, has issued two separate advisories recalling specific lots and batches of two drugs: a cholesterol-lowering medication and a drug to fight tuberculosis and other infections.

The Philippine regulatory agency identified the recalled products as Simvastatin 20 mg tablet sold under the brand names Novovast, Squastatin and Qvast, and Rifampicin 200 mg/5mLsuspension, the Manila Bulletin reports.

The affected Novovast products are lot number 13P378B manufactured by Square Pharmaceuticals in Parañaque, Philippines. The agency said this lot has been recalled from the market “due to the result of FDA laboratory analysis that the particular lot failed the dissolution test conducted.” A pill or capsule’s dissolution rate is important to the proper release of a drug’s ingredients and the drug’s effectiveness.

Novovast is used to decrease total LDL-cholesterol, apolipoprotein B, and triglycerides and to increase HDL-cholesterol in the treatment of hyperlipidaemias, including hypercholesterolaemias and combined hyperlipidaemia (type IIa or type IIb hyperlipoproteinaemias), the Philippine FDA explains. The identical drug products Squastatin, Qvast and a generic brand with the same indication and manufacturer are also being recalled, according to the Manila Bulletin.

“The affected product lot presents safety risks and may cause therapeutic failure,” said the FDA, adding that all distributors, hospitals, retailers and pharmacies that have the affected lot are directed to discontinue further distribution, sale, and use.

In a separate advisory, the Philippine FDA announced the recall of Rifampicin 200 mg/5mLsuspension under the brand name Rifanid. The recalled products, manufactured by Concept Pharmaceuticals in India, are under batches C30002 with an expiration date of May 2016, and C30007 and C30008 with an expiration date of July 2016.

Based on its lab analysis, the agency “found that the impacted product batches did not conform to the specifications on the appearance of the product which should be ‘suspension should settle slowly and should readily re-disperse upon gentle shaking.’” In its analysis, the agency observed caking in the affected batches that made the suspension not readily re-dispersible and also prevented the suspension from being easily poured from the container.

These batches of the drug “present safety risks if the suspension is not homogenized before administration to the patient.” As a result of not being homogenized, some doses will have low potency and others will have higher potency of the active ingredient. “Erratic potency of doses unknowingly taken by the patient may possibly cause either therapeutic failure or toxicity,” the Philippine FDA explained.